GRAIL, Inc. (GRAL)
60.56
+1.96
(+3.35%)
USD |
NASDAQ |
Jun 11, 13:31
GRAIL Total Assets (Quarterly) : 2.803B for March 31, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 2.803B |
| December 31, 2025 | 3.178B |
| September 30, 2025 | 2.601B |
| June 30, 2025 | 2.703B |
| March 31, 2025 | 2.848B |
| December 31, 2024 | 3.142B |
| September 30, 2024 | 3.118B |
| June 30, 2024 | 3.270B |
| March 31, 2024 | 3.973B |
| December 31, 2023 | 4.557B |
| September 30, 2023 | |
| June 30, 2023 |
| Date | Value |
|---|---|
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | 727.47M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Apogee Therapeutics, Inc. | 1.294B |
| Evommune, Inc. | 322.46M |
| Arrowhead Pharmaceuticals, Inc. | 2.268B |
| Oncolytics Biotech, Inc. | 8.161M |
| Sangamo Therapeutics, Inc. | 59.96M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 302.79M |
| Shareholders Equity (Quarterly) | 2.501B |
| Debt to Equity Ratio | 0.0204 |
| Current Ratio | 11.74 |
| Net Debt Paydown Yield | 0.16% |